Welcome!

News Feed Item

Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End

LOS ALTOS, Calif., Aug. 18, 2014 /PRNewswire/ -- Globavir Biosciences, Inc. ("Globavir"), a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa.  Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration (FDA) approved drugs, through an established compassionate use regulatory pathway.  The discovery of the use of GBV006 for the treatment of infectious diseases was made at Stanford University School of Medicine (Palo Alto, CA).  Globavir has the worldwide exclusive license to develop and market GBV006.

Globavir Biosciences, Inc.

The component drugs of GBV006 have demonstrated efficacy against experimental models of Ebola infection at dosages already approved and well-tolerated by patients. GBV006 is effective at low micromolar concentrations against Ebola in vitro.  By relying on thousands of patient years of established safety data, Globavir hopes to rapidly introduce GBV006 as an experimental treatment in helping to control the West Africa outbreak. 

"The situation in West Africa is dire, and there is an immediate need for drugs able to reduce the impact of Ebola infection," said Shalabh Gupta, M.D., CEO of Globavir.  "By repurposing a combination of approved drugs to treat Ebola virus, Globavir has the potential to overcome many hurdles regarding safety and supply of experimental therapies.  We hope to quickly form partnerships to distribute this potentially life-saving drug to those who need it most."

Globavir's antiviral therapeutic platform has multiple drugs under development, which were discovered, tested and licensed from Stanford University. The company is evaluating several drug combinations for Ebola treatment.

GBV006 targets and inhibits several distinct stages of the viral lifecycle, including entry of the virus into the cell and maturation of new viruses within cells. These two processes are crucial to viral infections including Ebola, Dengue, and West Nile virus.  A distinctive feature of Globavir's technology as compared to other upcoming treatments in the area is that GBV006 targets human cellular machinery necessary for viral replication rather than targeting the viral proteins or DNA directly.  As a result, the technology can be utilized to treat diseases caused by different viruses within the same family or those that exploit the same host machinery for entry and replication.  A similar approach using GBV001 (a related therapy under development) has shown efficacy in animal models of Dengue virus infection and approval to begin clinical trials will be sought this fall.

About Ebola

Infection with the Ebola virus causes severe hemorrhagic fever and causes death in up to 90% of cases.  Ebola virus is a member of the family of RNA viruses known as Filoviridae.  Ebola transmission occurs through contact with bodily fluid of an infected patient and there is no currently available treatment for Ebola beyond supportive care. 

Globavir's lead therapeutic program has focused on the treatment of Dengue Fever, which is caused by Flaviviridae, another family of RNA viruses.  Both Ebola and Dengue Fever can cause a syndrome known as viral hemorrhagic fever, a severe illness associated with bleeding.  

A recent outbreak of Ebola in West Africa has killed over 1000 people, and is the largest outbreak recorded. 

About Globavir

Globavir Biosciences is an infectious disease company developing life-saving technologies for the diagnosis and treatment of some of the world's most deadly viral diseases.  Globavir is developing powerful combination drug therapies and diagnostic tests for the treatment of Dengue Fever, and is advancing a development candidate for the treatment of Ebola, GBV006.  Globavir is based out of Mountain View, California, USA, and has additional research facilities in Halifax, Nova Scotia, Canada operating as BioCycive Canada.

Globavir's diagnostic tests and test kits are ready to be marketed globally. The company has the leading blood-based molecular diagnostic test to detect Dengue infection as well as a platform for other viral detection tests.

Forward Looking Statements and Information

In order to provide Globavir's investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward looking statements. Words such as "believes," "anticipates," "hopes," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements about the development of Globavir's product candidates, their efficacy, potency and utility in the treatment of rare and infectious diseases, their potential to treat a broad number of human diseases and Globavir's studies. These forward-looking statements involve risks and uncertainties, many of which are beyond Globavir's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of Globavir's drug candidates and/or Globavir's technology platform; and any of Globavir's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable. Any of the foregoing risks could materially and adversely affect Globavir's business results.

Globavir does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Logo - http://photos.prnewswire.com/prnh/20140818/137091

SOURCE Globavir Biosciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.